Secured Retirement Advisors LLC Has $1.01 Million Position in Zimmer Biomet Holdings, Inc. $ZBH

Secured Retirement Advisors LLC raised its position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 127.3% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,285 shares of the medical equipment provider’s stock after buying an additional 5,760 shares during the quarter. Secured Retirement Advisors LLC’s holdings in Zimmer Biomet were worth $1,013,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of ZBH. Vanguard Group Inc. grew its stake in shares of Zimmer Biomet by 0.9% in the second quarter. Vanguard Group Inc. now owns 23,251,295 shares of the medical equipment provider’s stock valued at $2,120,751,000 after acquiring an additional 198,370 shares in the last quarter. Dodge & Cox boosted its holdings in Zimmer Biomet by 12.9% in the 2nd quarter. Dodge & Cox now owns 22,097,463 shares of the medical equipment provider’s stock valued at $2,015,510,000 after purchasing an additional 2,533,009 shares during the period. American Century Companies Inc. grew its position in shares of Zimmer Biomet by 8.7% during the 2nd quarter. American Century Companies Inc. now owns 5,709,370 shares of the medical equipment provider’s stock worth $520,752,000 after purchasing an additional 458,903 shares in the last quarter. Geode Capital Management LLC increased its holdings in shares of Zimmer Biomet by 1.4% during the second quarter. Geode Capital Management LLC now owns 5,124,776 shares of the medical equipment provider’s stock worth $465,480,000 after purchasing an additional 69,485 shares during the period. Finally, Primecap Management Co. CA raised its position in shares of Zimmer Biomet by 0.6% in the second quarter. Primecap Management Co. CA now owns 4,710,830 shares of the medical equipment provider’s stock valued at $429,675,000 after buying an additional 27,860 shares in the last quarter. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

Shares of ZBH stock opened at $90.23 on Friday. The business has a fifty day simple moving average of $94.30 and a 200 day simple moving average of $96.58. The company has a market cap of $17.88 billion, a P/E ratio of 22.33, a P/E/G ratio of 2.37 and a beta of 0.61. The company has a quick ratio of 1.39, a current ratio of 2.43 and a debt-to-equity ratio of 0.59. Zimmer Biomet Holdings, Inc. has a twelve month low of $85.33 and a twelve month high of $114.44.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, November 5th. The medical equipment provider reported $1.90 EPS for the quarter, topping the consensus estimate of $1.88 by $0.02. Zimmer Biomet had a return on equity of 12.85% and a net margin of 10.05%.The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.01 billion. During the same quarter in the previous year, the firm earned $1.74 earnings per share. The business’s quarterly revenue was up 9.6% on a year-over-year basis. Zimmer Biomet has set its FY 2025 guidance at 8.100-8.300 EPS. On average, sell-side analysts forecast that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current fiscal year.

Zimmer Biomet Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, January 30th. Shareholders of record on Tuesday, December 30th will be given a $0.24 dividend. The ex-dividend date is Tuesday, December 30th. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio (DPR) is currently 23.76%.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on ZBH shares. Canaccord Genuity Group cut their price target on Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating for the company in a research note on Monday, November 10th. Citigroup cut their target price on Zimmer Biomet from $98.00 to $94.00 and set a “neutral” rating for the company in a research report on Thursday, December 11th. Robert W. Baird restated a “neutral” rating and issued a $100.00 price target (down previously from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Evercore ISI cut their price objective on shares of Zimmer Biomet from $106.00 to $104.00 and set an “in-line” rating for the company in a research report on Tuesday, October 7th. Finally, Johnson Rice set a $112.00 price objective on shares of Zimmer Biomet in a research note on Wednesday, November 5th. One analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, twelve have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $107.50.

About Zimmer Biomet

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.